

Table 3. POM121 expression compared with the control group and the effect of clinical and laboratory characteristics on overall survival in ALL patients.

	N	Group 1 (POM121 expression higher than the mean of the control)			n	Group 2 (POM121 expression lower than the mean of the control)		
		3 rd year OS	10 th year OS	P (Log rank)		3 rd year OS	10 th year OS	P (Log rank)
Lymphadenopathy								
Yes	1	58	50	0.333	12	75	67	0.624
No	2	75	66		23	77	72	
	1							
	2							
Hepatomegaly								
Yes	1	66	66	0.257	16	74	67	0.558
No	5	66	45		19	79	74	
	9							
Splenomegaly								
Yes	1	78	71	0.075	15	72	65	0.461
No	4	40	40		20	80	74	
	1							
	0							
Relapse								
Yes	6	16	0	0.001	11	53	32	0.003
No	1	84	78		24	87	87	
	8							
CNS Involvement								
Yes	6	16	0	0.001	8	60	45	0.159
No	1	84	78		27	81	77	
	8							
Gender								
Boy	1	63	63	0.675	23	82	77	0.172
Girl	6	75	50		12	66	57	
	8							
Risk Group								
SRG	1	70	50	0.023	9	77	77	0.600
MRG	0	82	82		18	76	65	
	1							
	1							
HRG	3	66	66		8	75	75	
Family History of Cancer								
Yes	2	40	-	*	8	75	75	0.759
No	2	70	60		27	77	69	
	2							
Cell Type								
T-cell	8	88	88	0.066	5	60	60	*
B-cell	1	44	44		25	84	75	
	3							
Age								
Older than 6 years	1	65	55	0.688	16	63	63	0.165
2–6 years old	1	56	56		16	94	86	
	9							
Under 2 years old	4	100	75		3	67	33	
Anemia								
Yes	2	70	61	*	33	75	72	*
No	3	0	0		2	100	50	
	1							

Neutropenia								
Yes	1	100	-	*	14	93	79	0.347
No	2 3	65	56		21	65	65	
Thrombocytopenia								
Yes	1	78	72	0.002	24	74	65	0.334
No	8 6	34	17		11	82	82	
White Blood Cell								
Above 100,000	2	100	100	*	4	25	25	*
Below 100,000	2 2	58	55		31	84	76	
Above 50,000	5	100	100	*	8	44	44	0.046
Below 50,000	1 9	52	48		27	85	78	
Above 20,000	1	80	80	0.081	14	62	62	0.260
Below 20,000	0 1 4	57	44		21	86	76	

*: No statistical analysis was performed because there were fewer than six cases in the groups.